Inaedis
Spin-out from Princeton University (founded 2022) developing a room-temperature aerosol dehydration platform to convert liquid biologics and vaccines into dry powders for storage, transport and alternative delivery routes. The company provides R&D and laboratory-scale manufacturing services, has peer-reviewed publications validating the approach, and has received multiple government and foundation awards to advance commercialization.
Industries
Nr. of Employees
small (1-50)
Products
Room-temperature aerosol dehydration platform
Platform process that forms ultra-fine aerosols from liquid bioformulations and dries them at room temperature to produce stable dry powders without added heat or freezing.
Room-temperature aerosol dehydration platform
Platform process that forms ultra-fine aerosols from liquid bioformulations and dries them at room temperature to produce stable dry powders without added heat or freezing.
Services
Research and development services to develop and validate room-temperature powderized formulations of biologic drugs and vaccines.
Production services for generating laboratory-scale batches of dry powder biologic doses and preparation for pilot-scale manufacturing.
Formulation and aerosolization development for high-quality inhaled biologics and inhalable powder candidates.
Research and development services to develop and validate room-temperature powderized formulations of biologic drugs and vaccines.
Production services for generating laboratory-scale batches of dry powder biologic doses and preparation for pilot-scale manufacturing.
Formulation and aerosolization development for high-quality inhaled biologics and inhalable powder candidates.
Expertise Areas
- Thermostable vaccine and biologic formulation
- Aerosol-based dehydration and liquid atomization
- Dry powder inhalation formulation
- Stability and potency analytical testing
Key Technologies
- Room-temperature aerosol dehydration
- Submicron liquid atomization
- Aerosol-assisted particle synthesis
- Dry powder inhalation formulation
News & Updates
Phase I SBIR contract to advance room-temperature aerosol dehydration development for thermostabilization of heat-sensitive medical countermeasures, focusing on Modified Vaccinia Ankara (MVA).
NSF Phase II SBIR award to advance development of the room-temperature aerosol dehydration platform toward clinical-grade manufacturing and commercialization.
Accepted into a digital sciences accelerator cohort focused on enabling technologies for drug discovery and development including AI/ML support resources.
Peer‑reviewed study in the Journal of Pharmaceutical Sciences reporting improved outcomes on protein degradation and aerosol performance versus traditional drying methods based on a blinded validation study with a large pharmaceutical company.
Multiple grants and awards including NSF and NIH STTR grants, state Catalyst funding, a QED Proof-of-Concept award, and early investment/support from a university innovation center and a venture studio.
Phase I SBIR contract to advance room-temperature aerosol dehydration development for thermostabilization of heat-sensitive medical countermeasures, focusing on Modified Vaccinia Ankara (MVA).
NSF Phase II SBIR award to advance development of the room-temperature aerosol dehydration platform toward clinical-grade manufacturing and commercialization.
Accepted into a digital sciences accelerator cohort focused on enabling technologies for drug discovery and development including AI/ML support resources.
Peer‑reviewed study in the Journal of Pharmaceutical Sciences reporting improved outcomes on protein degradation and aerosol performance versus traditional drying methods based on a blinded validation study with a large pharmaceutical company.
Multiple grants and awards including NSF and NIH STTR grants, state Catalyst funding, a QED Proof-of-Concept award, and early investment/support from a university innovation center and a venture studio.